Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001

Fineline Cube Oct 12, 2024

Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...

Company Deals

Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development

Fineline Cube Oct 12, 2024

Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked...

Company Drug

Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B

Fineline Cube Oct 12, 2024

Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug...

Company Deals

Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries

Fineline Cube Oct 12, 2024

Indian pharmaceutical company Hetero has announced a new partnership with US healthcare giant Gilead Sciences...

Company Drug

Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market

Fineline Cube Oct 11, 2024

Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...

Company Drug

Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer

Fineline Cube Oct 11, 2024

Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...

Company Drug

Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors

Fineline Cube Oct 11, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...

Company Drug

Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma

Fineline Cube Oct 11, 2024

Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...

Company Deals

Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform

Fineline Cube Oct 11, 2024

Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience...

Company Deals

XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery

Fineline Cube Oct 11, 2024

XtalPi (QuantumPharm, HKG: 2228) a leading AI-driven drug discovery firm based in Shenzhen and known...

Company Drug

Roche’s Genentech Scores FDA Approval for Itovebi in Advanced Breast Cancer Treatment, Advancing Personalized Oncology

Fineline Cube Oct 11, 2024

Roche (SWX: ROG)’s Genentech, a leader in pharmaceutical innovation, has received approval from the US...

Company Drug

Johnson & Johnson’s Darzalex Combo Therapy Gets EMA Nod for Multiple Myeloma, Aims to Set New Standard

Fineline Cube Oct 11, 2024

Johnson & Johnson (NYSE: JNJ) has taken a significant step in expanding its oncology portfolio...

Company Drug

Jiangsu Hengrui’s SHR2554 Gets Priority Review for Lymphoma Treatment, Strengthening Global EZH2 Inhibitor Market

Fineline Cube Oct 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is on the brink of a breakthrough in...

Company Drug

Jiangsu Hengrui Secures FDA Nod for Generic Abraxane, Strengthening Oncology Portfolio

Fineline Cube Oct 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has achieved a first in the US market...

Company Medical Device

Roche’s VENTANA CLDN18 Assay Receives EU Approval, Enhances Targeted Therapy Options for Gastric Cancer

Fineline Cube Oct 11, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY) has secured CE Mark approval in the European Union for...

Company Drug

Biogen Gains FDA Breakthrough Status for Felzartamab in Kidney Transplant Rejection Treatment

Fineline Cube Oct 11, 2024

Biogen Inc. (NASDAQ: BIIB) has secured breakthrough therapy designation (BTD) from the U.S. Food and...

Company

Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand

Fineline Cube Oct 11, 2024

Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...

Legal / IP Policy / Regulatory

China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting

Fineline Cube Oct 11, 2024

The National Medical Products Administration (NMPA) of China has issued a draft proposal for the...

Company Drug Medical Device

Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China

Fineline Cube Oct 11, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have...

Company Medical Device

Sino Medical Sciences Secures NMPA Nod for Balloon Guided Catheter to Aid Vascular Procedures

Fineline Cube Oct 10, 2024

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received marketing...

Posts pagination

1 … 278 279 280 … 658

Recent updates

  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
  • Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Others

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.